The medicines regulator has approved a second weight-loss tablet to be sold in Australia, which US pharmaceutical giant Eli Lilly expects to be available for patients as early as this week.
US pharmaceutical giant Eli Lilly said on Tuesday the Therapeutic Goods Administration had approved its daily pill known as orforglipron, and marketed as Foundayo, adding that the stock would arrive in the coming days – making its product the first alternative to the monthly injections available in Australia.
Gift articles to anyone you choose each month when you subscribe.